Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another ... including weight gain, high blood sugar, and mood changes. The FDA’s review is based on data ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a supplemental Biologics License Application for Dupixent (dupilumab ... and a high number of blood eosinophils ...

constipation, upper respiratory tract infection, limb injury, and insomnia, according to Sanofi. The dupilumab studies were funded by Sanofi and Regeneron, the companies co-developing dupilumab.

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

1 Dupilumab Development Program Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...